Full Breakdown
Samsung Biologics to Acquire Swiss Peptide CDMO PolyPeptide Group in $1.8 B Deal
7/20/2026, 11:24:02 AM
Deal Overview
On 20 July 2026, Samsung Biologics announced an all-cash public tender offer to acquire 100 % of PolyPeptide Group AG, a Swiss contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients. The offer price of 44.31 Swiss francs per share values the transaction at 1.46 billion CHF (approximately 2.7 trillion won or $1.8 billion). Samsung Biologics expects the acquisition to close by the end of 2026, subject to shareholder approval and regulatory clearance.
Strategic Background
Samsung Biologics, a leading South Korean CDMO, has built its portfolio around antibody drugs, messenger RNA (mRNA) therapeutics, and antibody-drug conjugates (ADCs). Rapid growth in the global peptide therapeutics market—driven by glucagon-like peptide-1 (GLP-1) drugs for obesity and diabetes—prompted the company to diversify into peptide manufacturing. Industry analysts project the worldwide obesity-treatment market could reach $150 billion by 2035, creating strong demand for peptide-based APIs.
Companies and Leadership
- Samsung Biologics Co. – CEO John Rim leads the South Korean firm, which reported a 1.3 % dip in its shares early Monday following the announcement.
- PolyPeptide Group AG – Chairman Peter Wilden heads the Swiss CDMO, which was spun off from Ferring Pharmaceuticals’ peptide division in 1996. The company operates six manufacturing sites and R&D centers across Sweden, Belgium, France, the United States, and India, employing roughly 1,500 specialists.
Deal Terms and Scale
- Offer price: 44.31 CHF per share (? 40 % premium to the pre-rumor closing price).
- Total consideration: 1.46 billion CHF (? 2.7 trillion won, $1.8 billion).
- Shareholder structure: Draupnir Holding B.V., the largest shareholder, holds 55.65 % of PolyPeptide and has committed to tender its entire stake.
- Tender threshold: at least 66.7 % of total issued shares must be tendered for the offer to succeed.
- Expected closing: by 31 December 2026, with integration plans to delist PolyPeptide from the SIX Swiss Exchange.
Anticipated Impact on the CDMO Market
The acquisition expands Samsung Biologics’ geographic footprint, adding production capacity in Europe, the United States, and India. By integrating PolyPeptide’s peptide-process technologies and eco-friendly manufacturing methods, Samsung aims to offer a multimodality CDMO platform covering antibodies, ADCs, mRNA, and peptides. The deal is positioned to enhance proximity to major pharmaceutical clients, mitigate supply-chain risks, and generate immediate revenue from PolyPeptide’s existing contracts.
Official Statements & Responses
Samsung Biologics emphasized that the purchase “strengthens our production capacity, business portfolio and global footprint while expanding our CDMO offerings and competitiveness.” The company also noted plans to review further expansion of peptide production facilities in line with market growth. PolyPeptide’s board described the transaction as a means to “broaden customer offerings and strengthen competitiveness in the global peptide CDMO market.”
Criticism & Opposition
No public criticism or opposition to the transaction was identified in the available reports.
Conflicting Reports & Gaps
- Closing timeline: Some sources state the deal will close “by the end of this year,” while others specify “late 2026.” Both refer to the same calendar year but differ in precision.
- Company name: The target is referred to as “PolyPeptide Group” and “Polypeptide Group” across different reports, though both descriptions match the same Swiss CDMO.
Verbatim Quotes
- “After a comprehensive review of strategic options, the Board is convinced that Samsung Biologics' offer is compelling for our shareholders, delivering an attractive cash price and immediate, certain value today,” — Peter Wilden, Chairman, PolyPeptide
- “This acquisition is a strategic decision that strengthens our production capacity, business portfolio and global footprint,” — John Rim, CEO, Samsung Biologics
- “The addition of Samsung Biologics’ manufacturing capabilities and operational expertise will further strengthen both customer service and our competitive edge in the global peptide CDMO market,” — Peter Wilden, Chairman, PolyPeptide
- “PolyPeptide Chairman Peter Wilden called the agreement a game-changing chance that would speed up the Swiss firm's long-term growth while providing instant benefits to shareholders.” — Company announcement, Samsung Biologics
---
The transaction marks the largest biopharmaceutical M&A in South Korea’s history and signals Samsung Biologics’ decisive move into the fast-growing peptide therapeutics sector.
